Brief: Armata Pharma Doses First Patient In Phase 1B/2A Study Of Treatment Of Bacteremia Due To Staphylococcus Aureus
23/05/2022 13:48
May 23 (Reuters) - Armata Pharmaceuticals Inc ARMP.A :
* ARMATA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN
PHASE
1B/2A 'DISARM' STUDY OF AP-SA02 IN ADULTS WITH BACTEREMIA DUE TO
STAPHYLOCOCCUS AUREUS
Source text for Eikon: ID:nPn3tWVX3a
Further company coverage: ARMP.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Armata Pharmaceuticals
See all newsBrief: Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Delays Announcement Of Fourth Quarter And Full-Year 2025 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation
Armata Pharma jumps on US FDA nod for late-stage infection trial
Brief: Armata Pharmaceuticals Commissions cGMP Manufacturing Facility In Los Angeles